Back to Journals » Biologics: Targets and Therapy » Volume 4

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib

Total article views   HTML views PDF downloads Totals
11,494 Dovepress* 11,494+ 2,651 14,145
Totals 11,494 2,651 14,145
*Since 30 April 2010
+Since July 2016

View citations on Google Scholar